VolitionRx Limited (NYSE:VNRX) Director Buys $10,800.00 in Stock

VolitionRx Limited (NYSE:VNRX - Get Free Report) Director Guy Archibald Innes acquired 20,000 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were purchased at an average cost of $0.54 per share, with a total value of $10,800.00. Following the completion of the purchase, the director now directly owns 888,689 shares of the company's stock, valued at $479,892.06. This trade represents a 2.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

VolitionRx Stock Performance

Shares of NYSE VNRX traded down $0.02 during mid-day trading on Friday, reaching $0.55. 118,044 shares of the company's stock were exchanged, compared to its average volume of 189,495. The company's 50-day moving average is $0.50 and its 200-day moving average is $0.57. VolitionRx Limited has a 52-week low of $0.40 and a 52-week high of $0.90. The firm has a market capitalization of $57.07 million, a price-to-earnings ratio of -1.54 and a beta of 1.07.

Hedge Funds Weigh In On VolitionRx

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp boosted its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after buying an additional 28,579 shares during the period. Two Sigma Securities LLC purchased a new stake in VolitionRx during the fourth quarter worth approximately $29,000. Millennium Management LLC purchased a new stake in VolitionRx during the fourth quarter worth approximately $36,000. Finally, Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after buying an additional 1,481,000 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company's stock.

Analysts Set New Price Targets

VNRX has been the subject of several research analyst reports. HC Wainwright assumed coverage on VolitionRx in a research report on Tuesday, April 8th. They set a "buy" rating and a $2.50 target price for the company. D. Boral Capital reiterated a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a report on Wednesday, April 30th. Finally, Wall Street Zen started coverage on VolitionRx in a research report on Thursday, May 15th. They issued a "sell" rating on the stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.